PTPN11 and cancer: Thus, B16F10 cancer model differs from the mutant KRASG12C MIAPaCA‐2 cancer model, in which the effectiveness of SHP099 was reported to be cancer cell intrinsic and the effects of SHP099 were recapitulated by the genetic depletion of SHP2 in the cancer cells (Hao et al,2019).